NCT05265442 2024-10-31
DUNE
RECORDATI GROUP
Completed
Clinical Trials
41 trialsNCT06209970 2024-04-17
35kDa Hyaluronan Fragment Treatment of Colorectal and Rectal Cancer
Nakhia Impex LLC
Phase NA Completed
NCT01854229 2023-10-18
Prometra Post-Approval Study
Flowonix Medical
Phase NA Completed
NCT04938440 2023-08-01
Assessment of Updated Educational Materials for Instanyl®
Takeda
Completed
NCT01337089 2023-04-12
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Jazz Pharmaceuticals
Phase 3 Completed
NCT01361607 2023-04-12
SPRAY III
Jazz Pharmaceuticals
Phase 3 Completed
NCT01424566 2023-04-12
A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer
Jazz Pharmaceuticals
Phase 3 Completed
NCT02609828 2023-02-16
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
Pfizer
Phase 3 Completed
NCT03031938 2021-06-25
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
Pfizer
Phase 3 Completed
NCT00830180 2021-04-05
Open Label Extension In Cancer Patients
Pfizer
Phase 2 Completed
NCT03226574 2020-10-20
Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain
Sorrento Therapeutics, Inc.
Phase 1 Completed
NCT00684632 2020-08-28
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT04315831 2020-03-20
SOOTHE
Taiwan Mundipharma Pharmaceuticals Ltd.
Completed
NCT03176121 2020-03-18
STOP Pain
Taiwan Mundipharma Pharmaceuticals Ltd.
Phase 4 Completed
NCT03176199 2020-03-18
A Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Patients With Moderate to Severe Cancer Pain
Taiwan Mundipharma Pharmaceuticals Ltd.
Phase 4 Completed
NCT00656305 2020-02-05
ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
InSightec
Phase NA Completed
NCT00472303 2019-11-04
A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine
Grünenthal GmbH
Phase 3 Completed
NCT01091883 2019-03-13
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma
InSightec
Phase NA Completed
NCT02660229 2018-11-19
SWITCH
Mundipharma Korea Ltd
Phase 4 Completed
NCT01675622 2018-05-21
Immediate-Release Oxycodone Capsules Study in Cancer Pain
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 3 Completed
NCT01313780 2017-12-22
TOP
Mundipharma Korea Ltd
Phase 4 Completed
NCT00101998 2017-08-30
Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Completed
NCT01326689 2017-03-08
2246-004
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT01719757 2016-08-19
PROBE
Mundipharma Korea Ltd
Phase 4 Completed
NCT00929188 2016-01-22
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain
Janssen Research & Development, LLC
Phase 2 Completed
NCT00771199 2014-09-17
An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain
Janssen-Cilag Ltd.
Phase 4 Completed
NCT01060124 2014-04-29
An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Cancer Participants With Inadequately Controlled Pain by Non-Narcotic Analgesics
Janssen Korea, Ltd., Korea
Phase 4 Completed
NCT01532895 2014-03-18
Clinical Usefulness and Quality of Life of OROS Hydromorphone in Patients Who Have Not Been Treated With a Strong Opioid
Janssen Korea, Ltd., Korea
Completed
NCT00804076 2014-02-19
Gene Transfer for Cancer Pain
Diamyd Inc
Phase 1 Completed
NCT01621100 2013-09-06
Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients
Janssen Korea, Ltd., Korea
Phase 4 Completed
NCT01829828 2013-04-11
The Effectiveness of a Patient Self-reported Pain Scoring Tool and a Satisfaction Survey on Cancer Pain Management
Janssen Korea, Ltd., Korea
Completed
NCT01816503 2013-03-22
Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study
Janssen Korea, Ltd., Korea
Completed
NCT01309386 2013-03-13
A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants
Janssen Pharmaceutical K.K.
Phase 3 Completed
NCT01402830 2013-02-11
Case-control Study- Cancer Pain: Uncontrolled Pain as Depression Development Predictor in Oncologic Patients (Fentanyl)
Janssen-Cilag, S.A.
Completed
NCT00459277 2012-01-25
Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Archimedes Development Ltd
Phase 3 Completed
NCT00576017 2011-05-19
A Study to Evaluate the Safety and Effectiveness of Fentanyl-TTS Compared to Weak Opioids in Patients With Moderate to Severe Chronic Cancer Pain Previously Treated With NSAIDS (Non-steroidal Anti-inflammatory Drugs).
Janssen-Cilag, S.A.
Phase 4 Completed
NCT00216658 2011-01-24
Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -
Janssen Pharmaceutical K.K.
Phase 2 Completed
NCT00576173 2010-04-28
An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients
Johnson & Johnson Taiwan Ltd
Phase 4 Completed
NCT00410540 2010-04-27
A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.
Alza Corporation, DE, USA
Phase 3 Completed
NCT00410943 2010-04-27
Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain
Alza Corporation, DE, USA
Phase 3 Completed
NCT00911261 2010-02-15
Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain
Endo Pharmaceuticals
Phase 3 Completed